Spyre Therapeutics, Inc. — Form 8-K
Filed August 25, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 48/100
What the filing says
Spyre announced Phase 2 SKYWAY trial results for SPY072 (TL1A antibody) in rheumatoid arthritis: both doses demonstrated statistically significant benefits on primary endpoint (DAS28-CRP change) and key secondary/exploratory endpoints (ACR20, ACR50); safety profile was comparable to placebo. However, magnitude of effect did not meet the company's internal bar to prioritize monotherapy development in RA. The company will refocus on combination approaches and continue evaluating SPY072 in psoriatic arthritis and axial spondyloarthritis (topline Q4 2026) and in combination with IL-17A/F for hidradenitis suppurativa (late 2027/early 2028).
Why this rating
Mixed clinical results (efficacy shown but monotherapy bar missed) reduce near-term RA valuation but preserve pipeline optionality. Moderate blow to lead asset; company pivots to combinations, not transformational loss.
See more from August 25, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.